drug

(amlodipine besylate + indapamide + telmisartan)

Marketedupdated 2mo ago

by Azurity Pharmaceuticals Inc

Approved

community read0 votes

indications

investigational

Hypertension

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

Patent cliff

source: FDA Orange Book

first barrier falls

Jun 5, 2028

~1.9 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (4)

Jan 23, 2038formulationUS 10322117
Jan 23, 2038formulationUS 10799487
Jan 23, 2038formulationUS 12465599
Jan 23, 2038formulationUS 12465599

FDA exclusivities (3)

Jun 5, 2028NPNP1.9y
Jun 5, 2028NPNP1.9y
Jun 5, 2028NPNP1.9y

Data sources

ClinicalTrials.gov

last refreshed 40m ago

Found something off?

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?